June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Protein-Based Retinal Implant
Author Affiliations & Notes
  • Nicole Wagner
    Molecular and Cell Biology, University of Connecticut, Storrs, CT
  • Jordan Greco
    Chemistry, University of Connecticut, Storrs, CT
  • Robert Birge
    Chemistry, University of Connecticut, Storrs, CT
  • Footnotes
    Commercial Relationships Nicole Wagner, LambdaVision, Inc (E), LambdaVision, Inc (P); Jordan Greco, LambdaVision, Inc. (E); Robert Birge, LambdaVision Inc. (P), LambdaVision Inc. (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1384. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicole Wagner, Jordan Greco, Robert Birge; Protein-Based Retinal Implant. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1384.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To develop a protein-based retinal implant to restore vision for the millions of patients suffering from age-related macular degeneration (AMD) and retinitis pigmentosa (RP).

Methods: A flexible implant, consisting of multiple, oriented layers of bacteriorhodopsin (BR) on an ion-permeable, biologically inert substrate is generated by using electrostatic layer-by-layer adsorption. Bacteriorhodopsin, a highly stable, light-activated proton pump, generates a unidirectional proton gradient in response to incident light. This proton gradient activates acid-sensing ion channels (ASICs) on the bipolar and ganglion cells of the retina. The resulting implant was tested for the ability to stimulate the ganglion cells of P23H rat retinas ex vivo using extracellular recording.

Results: Studies using extracellular recording of retinal ganglion cells in excised P23H rat retinas show that pumping protons in the direction of the ganglion and bipolar cell milieu generates a neural response. Moreover, the activation efficiency, or ability to induce a neural response in P23H rat retinas ex vivo, correlates directly with the intensity of incident red light (~640 nm). Importantly, the light intensity required to induce a neural response is comparable to that of ambient light, a capability critical to the function of the implant in humans.

Conclusions: The preliminary results demonstrate the potential efficacy of BR as the photoactive medium in a protein-based retinal implant for the treatment of AMD and RP.

Keywords: 412 age-related macular degeneration • 702 retinitis • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.